Genscript Biotech Management

Management criteria checks 2/4

Genscript Biotech's CEO is Weihui Shao, appointed in Jul 2021, has a tenure of 3.33 years. total yearly compensation is $2.48M, comprised of 14.3% salary and 85.7% bonuses, including company stock and options. directly owns 0.034% of the company’s shares, worth €927.93K. The average tenure of the management team and the board of directors is 3.6 years and 1.7 years respectively.

Key information

Weihui Shao

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage	14.3%
CEO tenure	3.3yrs
CEO ownership	0.03%
Management average tenure	3.6yrs
Board average tenure	1.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Weihui Shao's remuneration changed compared to Genscript Biotech's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-US$177m
Mar 31 2024	n/a	n/a	-US$136m
Dec 31 2023	US$2m	US$353k	-US$95m

Compensation vs Market: Weihui's total compensation ($USD2.48M) is about average for companies of similar size in the German market ($USD1.95M).

Compensation vs Earnings: Insufficient data to compare Weihui's compensation with company performance.

CEO

Weihui Shao (44 yo)

3.3yrs

Tenure

US$2,477,000

Compensation

Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jiange Meng	Executive Chairman	9.3yrs	US$495.00k	0.013% € 362.7k
Weihui Shao	CEO & COO	3.3yrs	US$2.48m	0.034% € 927.9k
Ye Wang	Co-Founder	22.8yrs	US$659.00k	0.036% € 1.0m
Luquan Wang	Co-Founder & Non-Executive Director	no data	no data	0.030% € 824.7k
Fangliang Zhang	Co-Founder & Executive Director	1.9yrs	US$531.00k	no data
Li Zhu	Chief Strategy Officer & Executive Director	4yrs	US$320.00k	0.054% € 1.5m
Shiniu Wei	Chief Financial Officer	3.9yrs	no data	no data
Aylin Bilgin	Chief Marketing Officer for GenScript Life Science Group	no data	no data	no data

3.6yrs

Average Tenure

56yo

Average Age

Experienced Management: G51's management team is considered experienced (3.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jiange Meng	Executive Chairman	9.3yrs	US$495.00k	0.013% € 362.7k
Ye Wang	Co-Founder	9.5yrs	US$659.00k	0.036% € 1.0m
Luquan Wang	Co-Founder & Non-Executive Director	9.5yrs	no data	0.030% € 824.7k
Fangliang Zhang	Co-Founder & Executive Director	2.5yrs	US$531.00k	no data
Li Zhu	Chief Strategy Officer & Executive Director	4yrs	US$320.00k	0.054% € 1.5m
Carl June	Member of Advisory Board	less than a year	no data	no data
George Church	Member of Advisory Board	5.2yrs	no data	no data
Alphonse Galdes	Independent Non-Executive Director	less than a year	no data	no data
David Liu	Member of Scientific Advisory Board	less than a year	no data	no data
Yiu Leung Cheung	Independent Non-Executive Director	less than a year	no data	no data
Chenyang Shi	Independent Non-Executive Director	less than a year	no data	no data
Ethan Pan	Independent Non-Executive Director	less than a year	no data	no data

1.7yrs

Average Tenure

61.5yo

Average Age

Experienced Board: G51's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.

Genscript Biotech Management

Management criteria checks 2/4

Key information

Recent management updates

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

Genscript Biotech Corporation Announces Board Appointments

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Recent updates

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

New major risk - Share price stability

Genscript Biotech Corporation Announces Late-Breaking Long-Term Overall Survival Data from Cartitude-4 Study in Multiple Myeloma

Genscript Biotech Corporation Announces Board Appointments

First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023)

First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023)

Genscript Biotech Corporation to Report First Half, 2024 Results on Aug 09, 2024

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

Now 22% undervalued after recent price drop

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Now 22% undervalued after recent price drop

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

New major risk - Share price stability

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

New minor risk - Profitability

New minor risk - Share price stability

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold €159k worth of stock

Full year 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in FY 2021)

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

Now 20% undervalued

Less than half of directors are independent

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Genscript Biotech Corporation Announces Board Changes

Full year 2021 earnings released: US$0.17 loss per share (vs US$0.11 loss in FY 2020)

Less than half of directors are independent

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Board Member recently sold €246k worth of stock

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Key Executive recently sold €988k worth of stock

Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test

Hillhouse Capital Management, Ltd. completed the acquisition of 2.99% stake in Genscript Biotech Corporation (SEHK:1548) from GenScript Corporation.

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.052 loss in FY 2019)

Full year 2020 earnings released

Genscript Biotech Corporation to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: €1.40

Genscript Probio and Neoletix Announce Successful Completion of 200-Liter Gmp Production Runs of Recombinant Coagulation Fviii Based on A Novel Production Technology

New 90-day low: €1.06

New 90-day low: €1.08

Genscript Biotech Corporation Announces Board and Director Changes

New 90-day low: €1.25

Co-Founder recently bought €410k worth of stock

First half earnings released

New 90-day low: €1.28

First half earnings released

New 90-day low - €1.60

Genscript Biotech Corporation to Report Q2, 2020 Results on Aug 29, 2020

New 90-day low - €1.66

Genscript Biotech Corporation Announces Management Changes Effective 2 August 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure